ANTI-IL-1BETA (INTERLEUKIN-1BETA) ANTIBODY-BASED PROPHYLACTIC THERAPY TO PREVENT COMPLICATIONS LEADING TO VASO-OCCLUSION IN SICKLE CELL DISEASE.

摘要

This invention generally relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to also as "IL-1beta Compounds") in a therapy preventing manifestations and especially complications leading to subsequent damages, such as vaso-occlusion, in individuals being threatened by sickle cell disease (that is, especially homozygous HbS gene carriers, heterozygotes with sickle-beta-thalassemia with an SCD supporting combination of HbS gene and beta-thal gene, an individual with one sickle cell gene and one null alleleor an individual with hemoglobin SC disease).